Loading stock data…
Nyxoah SA (NYXH)
$1.40-0.07 (-4.76%)
Market ClosedLast close Jul 24
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nyxoah SA in the Healthcare sector is trading at $1.40 with a market capitalization of $154M. Wall Street consensus targets $8.34 (4 analysts), implying a +495.6% move over the next 12 months. The stock is currently near its 52-week low of $1.26, remaining 63.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 15 is oversold, raising the odds of a near-term bounce. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +495.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 15) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.37M↑ | $5.64M↑ | $1.97M↑ | $1.34M↑ | $1.06M |
| Gross Profit | $3.64M↑ | $3.63M↑ | $1.19M↑ | $850,000↑ | $658,000 |
| Operating Income | -$20.50M↓ | -$18.26M↑ | -$24.20M↓ | -$19.85M↑ | -$20.64M |
| Net Income | -$15.94M↑ | -$23.51M↑ | -$23.58M↓ | -$20.61M↑ | -$22.38M |
Peer Comparison
JNJUNHPFE
Fundamentals
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The c...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$153.89M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-233.18%
Volume
Today's trading volume
107,189
Recent News
Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Day
Nyxoah (NASDAQ:NYXH) used its investor day presentation to outline early U.S. launch progress for its Genio hypoglossal nerve stimulation system, address reimbursement questions and describe its path toward profitability. Chief Executive Officer Olivier Taelman said there is “a lot of excitement in
Nyxoah (ENXTBR:NYXH) Stock Fair Value Moves Lower After Capital Raise And Analyst Caution
Nyxoah’s latest analyst update includes a reduced fair value estimate, moving from €7.37 to €5.80, a cut of roughly 21% in the refreshed model. Street research links this lower price target to a mix of optimism around Genio’s product uptake, as well as caution around funding needs, execution risk and the recent capital raise. Read on to see how these shifting assumptions are reshaping the Nyxoah story and how you can keep track as the narrative evolves. Analyst Price Targets don't always...
Nyxoah (ENXTBR:NYXH) Stock Fair Value Moves Lower After Analyst Cuts And Capital Concerns
Nyxoah is under fresh scrutiny after analyst fair value estimates shifted from €9.0 to about €7.37 per share, an adjustment of roughly 18% that reflects a reset in price targets. Recent research links these cuts to more cautious assumptions around capital needs, valuation, and execution risk. At the same time, commentary still points to progress with the Genio launch and U.S. net revenue trends. As you read on, you will see how these changing targets, and the debate between bullish and...
Why Is NYXH Stock Falling Today?
The company priced its stock offering on Friday at a steep discount, with proceeds to be used to expand commercialization activities in the United States.
Nyxoah SA (NYXH) Q1 2026 Earnings Call Highlights: Strong U.S. ...
Nyxoah SA (NYXH) reports a 25% sequential U.S. revenue increase, while addressing production yield issues impacting gross margins.